专题：聚焦美股2026年第一季度财报 核心要点 麦当劳 一季度盈利与营收均 超出分析师预期 。 公司依靠高性价比套餐吸引食客，同时顾客单笔消费提升，带动同店销售额上涨。 麦当劳首席执行官克里斯・肯普钦斯基表示，即便身处 充满挑战的经营环境 ，公司仍交出强劲季度业绩。 美股盘前，这家快餐巨头股价涨幅超 3.13%。 投资者将在美东时间上午 8：30 开始的财报电话会议中，密切关注 油价走高挤压居民消费 是否对麦当劳业绩产生影响。 达美乐披萨、奇波雷墨西哥烧烤等餐饮企业均透露，自美国与伊朗冲突爆发、油价飙升后，3 月门店销售已出现走软。 以下为麦当劳实际业绩与华尔街预期对比（基于路孚特分析师调查）： 调整后每股收益：2.83 美元，预期 2.74 美元 营收：65.2 亿美元，预期 64.7 亿美元 麦当劳一季度净利润达 19.8 亿美元 ，折合每股收益 2.78 美元；去年同期净利润 18.7 亿美元，每股收益 2.60 美元。 剔除重组费用及其他一次性项目后，公司调整后每股收益为 2.83 美元。 季度净营收同比增长 9%，至 65.2 亿美元。 当季公司 全球同店销售额增长 3.8% ，接近市场一致预期的 3.7%。 在本土美国市场，同店销售额上涨 3.9%，主要由顾客到店 客单价提升 拉动。 麦当劳一方面主打高性价比产品，吸引预算敏感型消费者； 另一方面通过营销造势与新品创新，推出定价略高的高端品类。例如联动《超级马里奥银河大电影》《KPop 猎梦偶像》推出联名套餐， 不参与折扣促销 ；3 月初在美国限时上架超大款巨无霸汉堡 Big Arch，主打高端汉堡定位。 直营国际市场同店销售额同样增长 3.9%，涵盖法国、德国、澳大利亚等核心市场。 特许经营开发型国际市场同店销售额增长 3.4%，其中 日本 成为该板块一季度表现最佳市场。 责任编辑：郭明煜

和过去 4 个月来不断刷新的大模型排行榜类似，大模型初创公司们的融资金额与市值也在不断刷新着人们的想象力。 年初双双登陆港股上市的智谱及 Minimax 股价飙涨，智谱股价累计翻了 6 倍有余，最新市值已超越百度——虽然智谱去年营收仅为百度的 0.56%，且仍处于巨额亏损之中，但还是乱拳打死老师傅。 股市飙涨之际，那些尚未上市的大模型初创公司再度成为投资人们争夺的焦点。 昨日 (5 月 6 日)，Kimi (月之暗面) 被曝即将完成新一轮 20 亿美元融资，投后估值超过 200 亿美元，半年间估值翻了 4 倍有余。晚点统计称，Kimi 迄今累计融资金额已超 376 亿元人民币，是大模型初创公司中累计融资最多的公司。 刚刚开启外部融资的 DeepSeek 估值更是在短短几周内不断翻番。最早外界流传的 DeepSeek 估值不过 100 亿美元，等到阿里巴巴及腾讯下场后，DeepSeek 估值翻番至 200 亿美元。昨日，外媒报道称国家集成电路产业投资基金 (简称“国家大基金”) 正接洽投资 DeepSeek，最新估值或达 450 亿至 500 亿美元。 如果不出意外，今年我们或许将会见证一个史无前例的人工智能资本狂潮。海外 OpenAI、Anthropic 以及马斯克旗下合并了 xAI 的 SpaceX 都将在年内上市，三家公司合计估值超过 3 万亿美元。国内智谱与 MiniMax 双双上市后，市场也屡次传出 Kimi 及阶跃星辰正筹备港股上市消息。 但这远不是大模型热潮的顶点。考虑到市场越来越庞大的算力开支与 Token 消耗，这场融资大战或许才刚刚开始。 没上市的 Kimi 拿走了更多钱 月之暗面曾经是中国大模型初创公司中风头最盛的那家。它一度最受巨头青睐，先后拿到美团龙珠、阿里巴巴以及腾讯的投资。它也一度是市场中烧钱最为凶猛的那家，单月投流一度超过字节豆包、腾讯元宝，一时风头无两。 但在 2025 年初 DeepSeek-R1 横空出世之后，月之暗面一度陷入沉寂和摇摆。那时它最新发布的旗舰模型 Kimi K1.5 在 DeepSeek 的荣光下几乎没有什么水花，它过去依赖投流打法也在此之后不断被人指责，市场一片看衰声音。 过去一年是 Kimi 内部调整的一年。他们暂停了过去激进的 C 端投流打法，将目光重新聚焦在算法与模型层面，重视开源社区及模型编程能力。半年后...

Vericel press release ( VCEL ): Q1 GAAP EPS of -$0.12 beats by $0.03 . Revenue of $68.4M (+30.0% Y/Y) beats by $4.78M . Non-GAAP adjusted EBITDA increased 195% to $9.6 million, or 14% of revenue Operating cash flow of $16.4 million Free cash flow of $15.1 million Approximately $211 million in cash and investments, and no debt More on Vericel Vericel Corporation 2025 Q4 - Results - Earnings Call Presentation Vericel Corporation (VCEL) Q4 2025 Earnings Call Transcript Vericel Q1 2026 Earnings Preview Vericel secures $197M BARDA deal, boosting NexoBrid supply plans Seeking Alpha’s Quant Rating on Vericel

Dr Mike Skelton assessed Valdo Calocane the day after he assaulted a flatmate in Nottingham in 2022.

几百美金的悬赏，跨越半个世纪的死局。 20世纪最伟大的「题目魔术师」保罗·埃尔德什（PaulErdős）生前留下了几百个悬赏令，金额从50刀涨到5000刀。 50年里，无数数学天才熬秃了头，也没能拿走一分钱。 结果，Google DeepMind带着名为Aletheia（真理女神）的怪兽进场了。 上线仅7天，13道难题应声而碎。 论文链接：https://arxiv.org/abs/2601.22401 但最扎心的真相是：AI并不是比你更聪明，它只是比你更懂「洗稿」。 13/700的真相：AI真的在加速科学吗？ 「AI攻克百年数学难题」看起来很像爽文标题，听听就行，别被带了节奏。 数学这行只看硬指标。DeepMind这次祭出的Aletheia，底色根本不是什么「天才数学家」，而是一个冷酷的「顶级逻辑洗煤厂」 这套逻辑极其残酷，带着一股子硅谷大厂KPI导向的血腥味： 初始的流量层里，装着700个埃尔德什猜想。 随后，Gemini开启Deep Think模式，像不要钱一样大规模灌入算力，得出200个候选方案。 然后，这200个候选人经过自然语言验证器，剔除逻辑不通的部分，最后只剩下63个。 最后，经过专家级别的数学推演，得到13个真正具有数学原创意义的答案。 成功证明问题：Erdős problem#1051 700个问题里只解答出13个，转化率还不到2%。 其中，最具代表性的是对「Erdős-1051」猜想中关于无理数分布的证明。 听着很牛X，但DeepMind自己也承认，剩下的68.5%都是学术垃圾。 有些AI给出的证明过程长达几百页，读起来像是东拼西凑的论文。 在整个过程中，Aletheia像一个「自动审稿员」。Gemini负责狂暴输出，而验证器负责冷酷拒绝。 Gemini DeepThink处理数学猜想具体过程：https://www.youtube.com/watch?v=Nmv4YxpbhU8 更讽刺的是，人类数学家复核后发现，这13个所谓的「突破」，很大一部分属于数学界的「低垂果实」——太繁琐所以没人想做。 一位参与评审的组合数学专家曾私下感叹： AI目前的强项不是创造，而是清扫。 只要算力管够，这种靠暴力逻辑搜集、整理、强行出结果的路径，AI基本无敌。 潜意识剽窃：AI数学家的「洗稿」艺术 在这次DeepMind的成果展示中，出现了一个让学术界集体炸锅的...

India’s military is exploring alternative energy sources amid surging oil and gas prices caused by supply disruption from the Iran war, a trend that analysts say is set to accelerate among Asian countries heavily dependent on energy imports. According to local media reports, the Indian army plans to get biogas stoves to replace natural gas-fired appliances for cooking. It is also exploring the use of green fuels for army vehicles and administrative work, as well as solar and wind power for...

8岁读完高中、15岁拿下量子物理博士学位。这位天才少年宣布了第二个博士方向：用AI攻克人类衰老！在他眼里，死亡只是一个还没拼完的拼图。 8岁读完高中，15岁拿下博士学位。 这位来自比利时的神童Laurent Simons，答辩结束后，没有庆祝，没有休息。 第一时间，他便和父亲一起飞回了德国慕尼黑。 接下来，Simons要开启人生第二个博士方向：用AI攻克人类衰老，实现永生。 他说，死亡只是一个还没拼完的「拼图」。 8岁读完高中，神童的开挂人生 打开Laurent Simons的个人履历，简直就是一个彻底「开挂」的人生。 4岁上小学，6岁读完全部课程，8岁高中毕业。别人刚上三年级，他已经把K-12全部走完了。 9岁，他又进入荷兰埃因霍温理工大学攻读电气工程学士。 原本计划10个月读完三年课程，后来因为与校方在毕业时间上产生分歧，他转到比利时安特卫普大学，改修物理学。 三年的学士课程，他仅用18个月读完。12岁那年，他获得了量子物理学硕士学位。 紧接着，他又在15岁这一年，拿下了量子物理学博士学位。 研究方向，是量子物理中最硬的那一块：量子态的相干性与退相干机制。 Simons的IQ 145，绰号「小爱因斯坦」 15岁博士「疯狂转向」，从量子物理到人类衰老 拿到量子物理博士学位后，Simons做了一个让导师都没预料到的选择： 他申请了第二个博士学位，方向是医学与AI的交叉领域。 研究目标只有一个，那便是理解人类衰老的底层机制，并找到延长健康寿命的路径。 这个想法不是突然冒出来的。早在11岁时，西蒙斯就确定了这个方向。 原因很痛——Simons的祖父母都患有心血管疾病。 我不希望其他人也经历失去至亲的痛苦。 我的目标是更深入地理解疾病的过程，创造能改变热人类生活方式和健康状况的解决方案，而不仅仅是缓解症状。 这不是一个15岁少年的「浪漫幻想」。 Simons给出了非常具体的研究框架，他把衰老看作一个「多系统耦合」的复杂工程问题—— 生物学：提供了衰老的表征（端粒缩短、DNA损伤累积、蛋白质折叠错误、线粒体功能衰退）； 物理学：提供了理解这些过程的底层工具（热力学、信息论、量子生物学）； 工程学：提供了干预手段（基因编辑、药物设计、纳米机器人）。 而AI，是把这三条线串起来的「胶水」。 在Simons看来，死亡就像一个极其复杂的拼图，碎片散落在生物学、物理学和工程学里。 过...

不知道大家有没有跟我一样的感受：在AI这个时代，字节跳动又变牛了。 说"又"，是因为中间有过一段让人觉得它可能要掉队的时期。要理解这件事，得先回到字节上一次是怎么牛起来的。 移动互联网时代人和信息怎么连接？它产生了两种形态——人找信息，这是搜索；信息找人，这是推荐算法。字节靠后者在那个时代做到了最牛，今日头条、抖音，它把"信息找人"这件事做到了极致。 然后AI来了，中间插入了一个新节点。 现在的逻辑变成：人找AI，AI找信息，AI再把信息呈现给人。这不只是工具的升级，这是人和信息之间整个连接方式的重构。在这个新的结构里，谁站在AI这个节点上，谁就拿到了新时代的主动权。GEO这个行业存在的意义，就是因为这个节点变了。 我们做GEO，研究的就是这件事。研究到最后发现，在中国，这个节点上站着的是豆包。月活2.26亿，日活破亿，几乎成了唯一的选择。 时代切换的时候，大多数上一个时代的顶尖公司都掉队了。腾讯到现在也没有一款真正站得住的AI产品。这不是嘲讽，这是时代的正常代价。 但字节不一样，它既不是模型做的最早的，也不是技术最顶尖的，它凭借着一套逻辑和打法，在当下这个AI时代，又占据了最关键的位置。 它是怎么做到的？ 战略清醒：放弃模型第一，才拿到了真正的第一 2023年3月，ChatGPT的冲击波传到中国，所有大厂同时做出了同一个判断：这是一次必须参与的技术革命。 于是大家纷纷下场，争相发布自己的大模型，争的是技术排名，争的是媒体头条，争的是"中国GPT3.5"的名号。 百度押注文心一言，阿里押注通义千问，各家的发布会一场接一场，整个行业弥漫着一种氛围：谁的模型参数最多、跑分最高，谁就是这场革命的主角。 字节跳动在那个时间节点，内部既没有成型的基础模型，也没有明确的AI战略方向。按常理来说，这是一个落后者的处境。 但字节做了一个在外人看来很奇怪的决定：主动放弃争模型第一，反过头来做产品。 他们想清楚了一件事：基础模型的竞争是一场烧钱无底洞，技术迭代极快，今天的第一明天就可能被超越，大部分模型最终都会被市场淘汰。 更重要的是， 模型再强，最后也必须落在产品上才能触达用户。 既然如此，为什么不直接跳过这场军备竞赛，去做用户真正会用的产品？做产品，才是字节真正擅长的事，也是他们真正能建立护城河的地方。 这个判断的清醒之处在于：它需要抵抗巨大的外部压力。当所有竞争对手都在高调发布模...

格隆汇5月7日｜据霍尼亚拉消息，所罗门群岛总督大卫·蒂瓦·卡普7日致信议会议员，宣布新总理选举将于5月15日举行。所罗门群岛议会7日投票通过对总理马内莱的不信任动议，原政府须作为看守政府履职至选出新总理。根据宪法，新总理将由议会从现任议员中选出。候选人提名工作将于8日至10日进行。

格隆汇5月7日｜中瓷电子今日在业绩说明会上表示，公司开创了我国光通信器件陶瓷外壳产品领域，氮化铝薄膜基板已实现批量供货，已成为国内规模最大的高端电子陶瓷外壳制造商，光模块封装用陶瓷外壳和基板市占率处于全球头部地位。

Payoneer Global press release ( PAYO ): Q1 GAAP EPS of $0.06 beats by $0.02 . Revenue of $261.6M (+6.1% Y/Y) beats by $7.31M . 2026 guidance is as follows: Revenue $1,100 million - $1,140 million vs. consenssus of $1.11B Transaction costs ~15.0% of revenue Adjusted EBITDA 1 $285 million to $295 million Click to enlarge More on Payoneer Global Payoneer: Never Happy Despite Hidden Growth Payoneer Global Inc. 2025 Q4 - Results - Earnings Call Presentation Payoneer Global Inc. (PAYO) Q4 2025 Earnings Call Transcript Payoneer Global Q1 2026 Earnings Preview Payoneer signals 12% core revenue growth and $90M adjusted EBITDA target for 2026 amid upmarket shift and stablecoin expansion

(RTTNews) - Vital Farms (VITL), an Ethical Food Company, on Thursday reported loss in the first quarter compared with the previous year. The company has lowered net revenue and adjusted EBITDA guidance.

格隆汇5月7日｜波士顿联储行长苏珊·柯林斯表示，她认同上周货币政策会议上几位委员对会后声明措辞的反对意见。相关措辞暗示，美联储最终将恢复降息。柯林斯在接受采访时表示，她“强烈支持”维持利率不变的决定，但她也倾向于调整声明措辞，以“不要与那种常被理解为预设下一步行动将是降息的表述靠得太近”。达拉斯联储行长洛丽·洛根、克利夫兰联储行长贝丝·哈马克和明尼阿波利斯联储行长尼尔·卡什卡里都支持4月29日按兵不动，但反对他们所称声明中包含的“宽松倾向”。柯林斯今年并非联邦公开市场委员会的投票委员。但她对声明措辞的看法，凸显出委员会内部正持续转向，不再考虑近期降息的可能性。柯林斯的言论表明，她属于越来越多希望美联储更清楚传递这样一种信号的官员之一，即下一步行动可能是降息，也可能是加息。

About 120 journalists and broadcast staff expected to protest about pay freeze as STV invests in new radio station UK politics live – latest updates Coverage of Scotland’s election counts by STV, the commercial broadcaster, is expected to be heavily hit by strike action in an escalating dispute over pay. The National Union of Journalists and the technical union Bectu have targeted STV’s election reporting for their second strike this year in protest at its decision to impose a company-wide pay freeze after a significant fall in revenues. Continue reading...

S&P 500 Index futures are up 0.1% as of 7:45 a.m. in New York as traders wait for updates on a possible US-Iran peace deal. Nasdaq 100 futures are little changed Dow Jones Industrial Average futures are up 0.2% The MSCI World Index is up 0.2% Here are some of the biggest US movers before the bell: Magnificent Seven stocks: Tesla (TSLA) +1.7%, Alphabet (GOOGL) +1.1%, Nvidia (NVDA) +0.1%, Microsoft (MSFT) +0.7%, Amazon (AMZN) +0.3, Meta Platforms (META) +0.02%, Apple (AAPL) -0.1% Albemarle (ALB) climbs 6% after the chemical producer reported net sales for the first quarter that beat the average analyst estimate. Arm Holdings ADRs (ARM) drop 8% after the chip company reported weak fourth-quarter royalty revenue, hurt by sluggishness in the smartphone industry. Daiwa’s analyst notes that there was weaker demand for lower-end phones due to higher memory cost. Celsius Holdings (CELH) rises 4% after the energy drink maker’s first quarter adjusted Ebitda and revenue beat consensus estimate. Coherent (COHR) drops 3% as analysts note that the optical communications company’s gross margins underwhelmed. DoorDash (DASH) jumps 10% after the delivery firm gave a forecast for order value in the current period that topped analyst estimates, signaling healthy consumer demand for its services in the US and international markets. Fluence Energy (FLNC) jumps 31% after the company reported a narrower-than-estimated second-quarter adjusted Ebitda loss. Additionally, Fluence maintained its 2026 total revenue forecast, which has a midpoint above the average analyst estimate. Fortinet (FTNT) gains 15% after the cybersecurity company forecast earnings that beat the average analyst estimate. The company also boosted its full-year revenue outlook. Analysts note particular strength at its hardware business. Fastly (FSLY) slumps 25% after the software company reported first-quarter earnings, a report that wasn’t strong enough to extend a rally that has lifted shares nearly 300% off a February lo...

Getty Images Introduction In my view, Webster Financial today is a bank that is fully priced in, because the Santander deal, a strong HSA Bank segment, and good operational quality are almost fully reflected in the share price, and the worsening credit quality and pressure on margins limit further growth potential. Webster Financial Corporation ( WBS ) operates as a specific regional bank, whose valuation is dictated not only by the operational results but also by the $12.3 billion merger with Banco Santander, which was announced in February 2026. By the deal's conditions, shareholders should receive $48.75 in cash and 2.0548 Santander shares for every WBS share, which is why the current market price, at around the $72 level, is directly tied to this deal's arbitrage. The 2026 Q1 results show $735.9 million in revenues, which is a 4.4% growth year over year. Adjusted EPS reached $1.57, though the net interest margin decreased to 3.36%, compared to 3.48% last year. This shows an increasing deposit interest cost, which is just partly compensated by the 8.6% growth in the loan portfolio, which reached $57.2 billion. An essential bank's difference to others remains the HSA Bank segment, which manages over $10.7 billion in health savings account deposits, which ensures a cheaper and more stable capital base than traditional regional bank models. Currently, shares are traded with an 11.8x P/E and a P/B ratio of 1.26x, which is over the five-year average. Such valuation shows that the market already priced in a lot of the success from the merger. Even though the bank's CET1 capital adequacy ratio is a solid 11.42% and the efficiency ratio reached a low level of 46.8%, for investors, this is not a growth story anymore but rather a waiting phase until the deal ends at the end of 2026. Business overview Webster Financial Corporation's main operational transformation is in the specialized commercial bank, whose growth is maintained by the Healthcare Financial Services segment....

CoreWeave (NASDAQ: CRWV) has one of the boldest AI infrastructure stories in the market, with major contracts from companies like Meta (NASDAQ: META) and Anthropic, supporting a significant growth runway. But its debt-fueled expansion creates a major test for investors: can demand, backlog, and execution turn this risky build-out into a long-term winner? Stock prices used were the market prices of April 25, 2026. The video was published on May 4, 2026. Continue reading

Citigroup bets on CEO Fraser's overhaul to aim for 11% to 13% profitability Reuters

NetScout Systems press release ( NTCT ): Q4 Non-GAAP EPS of $0.52 beats by $0.06 . Revenue of $203M (-1.0% Y/Y) beats by $4.09M . Product revenue for fiscal year 2026 was $370.1 million, up from $359.9 million in fiscal year 2025. Service revenue for fiscal year 2026 was $489.3 million, up from $462.8 million in fiscal year 2025. NETSCOUT’s income from operations (GAAP) for fiscal year 2026 was $109.8 million, with a GAAP operating margin of 12.8%. This compares with a loss from operations (GAAP) for fiscal year 2025 of $367.6 million, which included total non-cash goodwill charges of $427.0 million. Non-GAAP income from operations for fiscal year 2026 increased to $218.5 million, with a non-GAAP operating margin of 25.4%. This compares with non-GAAP income from operations of $195.1 million and non-GAAP operating margin of 23.7% for fiscal year 2025. NETSCOUT’s net income (GAAP) for fiscal year 2026 was $95.5 million, or $1.30 per share (diluted). This compares with a net loss (GAAP) of $366.9 million, or $(5.12) per share (diluted), for fiscal year 2025, which includes the non-cash goodwill charged previously mentioned. Non-GAAP net income for fiscal year 2026 was $182.0 million, or $2.48 per share (diluted). This compares with non-GAAP net income of $160.4 million, or $2.22 per share (diluted), for fiscal year 2025. The Company’s adjusted EBITDA for the fiscal year 2026 was $228.1 million, or 26.5% of total revenue, versus adjusted EBITDA of $208.4 million, or 25.3% of total revenue for fiscal year 2025. During fiscal year 2026, NETSCOUT repurchased approximately 2.5 million shares of its common stock for an aggregate of approximately $60.8 million at an average price of $24.29 per share through its share repurchase program. Financial Outlook For fiscal year 2027, the Company is providing the following outlook, which reflects expected continued growth and margin expansion: Revenue is expected to be in the range of $885.0 million to $915.0 million, which implies ye...

(RTTNews) - Lantheus Holdings Inc. (LNTH) revealed earnings for its first quarter that Increases, from the same period last year

Americold Realty Trust ( COLD ) and EQT ( EQT ) said Thursday they have formed a new joint venture focused on owning, operating, and developing temperature-controlled warehouse facilities across North America. Under the agreement, Americold Realty Trust will contribute 12 U.S. cold storage facilities valued at more than $1.3B to the venture. The portfolio includes about 124M cubic feet of refrigerated capacity and more than 400,000 pallet positions. EQT’s Active Core Infrastructure fund will acquire a 70% stake in the venture, while Americold will retain a 30% interest and continue managing day-to-day operations. Americold expects to receive roughly $1.1B in net cash proceeds, which it plans to use to repay debt. "This joint venture is an important strategic step…strengthening our balance sheet," said Americold CEO Rob Chambers. The transaction is expected to close in the third quarter of 2026. Americold shares up +2.7% in premarket trading. More on Americold Realty Trust, EQT EQT Corp.: Recent Selloff Further Highlights Underpricing EQT Corporation (EQT) Q1 2026 Earnings Call Transcript EQT Posted A Giant Quarterly Comparison As Expected Americold Realty Trust FFO of $0.29 beats by $0.10, revenue of $629.9M beats by $27.75M Americold Realty Trust, Lineage downgraded at Barclays on industry challenges

Collegium Pharmaceutical press release ( COLL ): Q1 Non-GAAP EPS of $1.76 beats by $0.24 . Revenue of $193.5M (+8.8% Y/Y) beats by $9.04M . Generated pain portfolio net revenues of $154.6 million in the 2026 Quarter, up 4% year-over-year. Generated Belbuca® net revenue of $52.6 million in the 2026 Quarter, up 2% year-over-year. Generated Xtampza® ER net revenue of $50.8 million in the 2026 Quarter, up 7% year-over-year. Financial Guidance for 2026 Product Revenues, Net $805 - $825 million JORNAY PM Revenue, Net $190 - $200 million Adjusted EBITDA $455 - $475 million Click to enlarge More on Collegium Pharmaceutical Collegium Pharmaceutical, Inc. (COLL) Discusses Acquisition of AZSTARYS to Expand ADHD Portfolio and Accelerate Growth - Slideshow Collegium Pharmaceutical: Another M&A Episode Adds To An Intriguing Case Collegium Pharmaceutical, Inc. (COLL) Discusses Acquisition of AZSTARYS to Expand ADHD Portfolio and Accelerate Growth Transcript Collegium Pharmaceutical Q1 2026 Earnings Preview Collegium to buy ADHD medicine Azstarys for up to $785M

专题：聚焦美股2026年第一季度财报 核心要点 派乐腾公布第三财季财报， 营收超出华尔街分析师预期 。 公司设备销量、订阅收入及盈利能力均实现增长。 首席执行官彼得・斯特恩向 CNBC 表示，上调订阅定价是基于 价值定位 的合理举措。 2025 年 9 月 30 日周二，美国纽约派乐腾总部媒体预览活动上亮相的智能跑步机 Tread + 与健身单车 Bike+。 派乐腾全面更新硬件产品线并上调售价，这也是新任管理层为扭转公司多年低迷颓势推出的首批重大举措之一。 派乐腾周四公布第三财季财报： 营收好于华尔街预期 ，但每股收益略低于市场预估。 公司表示，设备销量与订阅收入双双增长，拉动整体销售额及盈利能力提升， 自由现金流大增近 60% 。 公司首席执行官彼得・斯特恩接受 CNBC 采访时称：“财报首先要体现财务表现，从战略布局和经营结果来看，本季度整体表现相当不错。” 以下为截至 3 月 31 日的季度业绩对比（基于路孚特分析师调研预期）： 每股收益：实际 6 美分，预期 7 美分 营收：实际 6.309 亿美元，预期 6.176 亿美元 本季度公司净利润 2640 万美元，折合每股收益 6 美分；而去年同期亏损 4770 万美元，折合每股亏损 12 美分。 当期营收 6.309 亿美元，同比小幅上涨约 1%，上年同期为 6.24 亿美元。 派乐腾上调全年财年营收指引，预计总营收介于 24.2 亿 —24.4 亿美元 ，较上季度给出的指引上调区间下限。 数据显示： 互联健身订阅相关收入达 2.029 亿美元，略低于去年同期的 2.055 亿美元，但高于 1.96 亿美元的市场预期；整体订阅收入达 4.28 亿美元， 同比增长 2% ，同样超出预期。 不过， 付费互联健身订阅用户数同比下滑 ，降至 266 万人。 这家智能健身企业长期受业绩疲软、销售低迷困扰，此前曾预计本季度弱势行情仍将延续。公司已着手 重塑产品矩阵 ，并于近期上调健身硬件及订阅套餐价格。 斯特恩认为此次调价举措合理恰当： “我们深知当前经济环境下民众普遍有生活压力，且对不同人群影响各异。即便如此，我们认为二季度启动调价时机成熟。自上一次调整订阅资费后的三四年间，我们已为用户叠加了大量增值服务与内容价值。” 此外，派乐腾持续缔结新合作、尝试新策略以挽回用户。 公司上月宣布与 Spotify（声破天） 达成...

JHVEPhoto/iStock Editorial via Getty Images After the bell on Tuesday, we received first-quarter results from Advanced Micro Devices ( AMD ). The chipmaker has been one of the market's biggest winners over the past year, surging more than 327% as the company's products help to power the Artificial Intelligence ("AI") revolution. With another solid quarter reported and decent current period guidance given, shares continue to set new highs almost daily. Previous coverage of the name It was back in early February that I last looked at AMD, a little after we got the company's fourth-quarter results . Despite top- and bottom-line beats and solid guidance, shares pulled back on the news, which I believed provided a buying opportunity for investors. Since that time, AMD shares have surged by 109%, dramatically outpacing the S&P 500's nearly 8% gain. Solid Q1 results For the quarter, AMD reported total revenues of $10.25 billion, growth of nearly 38% over the prior year period. This was the 14th straight beat of analyst estimates, although it was the smallest dollar beat since last year's Q1, as the street's expectations have certainly risen. Growth was led by the Data Center segment, which showed a 57% top line increase for the second straight Q1 period. Data Center growth accelerated nicely for the third straight quarter after reaching a recent low of just 14% back in Q2 2025. Client and Gaming revenues were up 23%, while Embedded revenues rose by 6%. On the margin front, non-GAAP gross margins rose by one percentage point to 55%. There was a similar one-point rise in operating margins to 25%, as operating expense growth was a little hotter than the overall revenue rise. AMD reported a 45% rise in non-GAAP net income to over $2.26 billion, although adjusted EPS growth was a little lighter due to a slight rise in the diluted share count. Non-GAAP EPS came in at $1.37, beating the street by 8 cents and up 43% year over year, while being the company's second-largest beat in ...

JHVEPhoto/iStock Editorial via Getty Images After the bell on Tuesday, we received first-quarter results from Advanced Micro Devices ( AMD ). The chipmaker has been one of the market's biggest winners over the past year, surging more than 327% as the company's products help to power the Artificial Intelligence ("AI") revolution. With another solid quarter reported and decent current period guidance given, shares continue to set new highs almost daily. Previous coverage of the name It was back in early February that I last looked at AMD, a little after we got the company's fourth-quarter results . Despite top- and bottom-line beats and solid guidance, shares pulled back on the news, which I believed provided a buying opportunity for investors. Since that time, AMD shares have surged by 109%, dramatically outpacing the S&P 500's nearly 8% gain. Solid Q1 results For the quarter, AMD reported total revenues of $10.25 billion, growth of nearly 38% over the prior year period. This was the 14th straight beat of analyst estimates, although it was the smallest dollar beat since last year's Q1, as the street's expectations have certainly risen. Growth was led by the Data Center segment, which showed a 57% top line increase for the second straight Q1 period. Data Center growth accelerated nicely for the third straight quarter after reaching a recent low of just 14% back in Q2 2025. Client and Gaming revenues were up 23%, while Embedded revenues rose by 6%. On the margin front, non-GAAP gross margins rose by one percentage point to 55%. There was a similar one-point rise in operating margins to 25%, as operating expense growth was a little hotter than the overall revenue rise. AMD reported a 45% rise in non-GAAP net income to over $2.26 billion, although adjusted EPS growth was a little lighter due to a slight rise in the diluted share count. Non-GAAP EPS came in at $1.37, beating the street by 8 cents and up 43% year over year, while being the company's second-largest beat in ...

AMD: New Highs Just Keep Coming Seeking Alpha

In this article AMZN NVO Follow your favorite stocks CREATE FREE ACCOUNT Amazon Pharmacy Kiosk Source: Amazon Pharmacy Amazon.com said on Thursday its pharmacy will stock Novo Nordisk's Ozempic pill to treat type 2 diabetes at its kiosks and ⁠offer same-day delivery of the drug. Novo's Ozempic uses the active ingredient semaglutide to control blood sugar in people with type 2 diabetes, where the body either fails to produce or resists insulin, the hormone regulating blood sugar. Amazon has been stocking Novo's weight-loss drug Wegovy, which uses the same active ingredient as Ozempic, ⁠since ‌January. It announced in April it would ⁠also stock rival Eli Lilly's Foundayo pill for weight loss. "Amazon Pharmacy continues to provide customers expanded selection and reliable, convenient access to the latest treatments like the Ozempic pill for type 2 diabetes," ‌said Tanvi Patel, a vice president at Amazon. "We are making it easy for customers to get the medication they need to stay healthy." Amazon began delivering GLP-1 medications, a class of drugs to treat diabetes and obesity, in 2021. It does not stock the injectables in kiosks because they need to be refrigerated, unlike the pill versions. Half of ⁠Amazon's U.S. customers have access to same-day delivery and all customers receive their medications within ‌four days. Amazon will offer same-day delivery for Ozempic ‌to about 3,000 locales and will expand access to 4,500 by year-end. Customers with a prescription can order the pill through Amazon Pharmacy for $149 per month for cash or through insurance, the ⁠company said. The lowest price with insurance is $25, Amazon said in its ⁠release. Novo's Wegovy pill is stocked in five kiosks in ⁠California, where customers can pick up the drugs at Amazon's One Medical locations following a medical appointment. Amazon announced the kiosks to address barriers to access and limit shipping expenses ‌for customers, first targeting drugs like antibiotics, blood pressure medicines ...

Stevanato (STVN) delivered earnings and revenue surprises of +6.56% and +2.32%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

财联社5月7日讯（记者 陈抗） *ST棒杰 （002634.SZ）的内部治理矛盾进一步升级。公司今日早间公告称，5月6日召开的第六届董事会第二十七次会议审议通过了两项关键议案，分别是《关于不予提交控股股东临时提案至股东会审议的议案》及《关于不予提交持股3%以上股东临时提案至股东会审议的议案》。两项议案均以7票同意、2票反对获得通过，董事长曹远刚及非独立董事刘俊投出反对票，并对董事会程序合法性提出质疑。 在公司处于重整关键阶段的背景下，上述提案涉及董事会席位调整、重整协议审议等事项，似乎预示着一场更深层的博弈。 两项提案引发程序争议 此次被董事会拒绝提交的第一项提案，来自控股股东上海启烁，这份临时提案的核心诉求是提请罢免夏金强（总经理）、刘姣两名董事职务。第二项提案则来自持股3.17%的自然人股东任欣，内容是提请股东大会审议公司与美年大健康签署的《重整投资协议》。 从表面看，这两项提案分别对应“董事会成员调整”和“重整协议表决”。但放到*ST棒杰当前的特殊处境里，前者关系到董事会席位和公司治理结构，后者关系到重整投资方案能否顺利落地，以及公司未来控制权归属。 在董事会表决中，曹远刚和刘俊投了反对票。两人的核心意见相对一致：董事会作为召集人，只有形式审查权，不能实质审核；而股东提交的两项议案没有违法违规，也在股东会职权范围内，应及时公告并提交股东会审核。 曹远刚进一步认为，《重整投资协议》涉及公司股本增加，依法应当由股东会决议，而不是董事会直接拦下。他还指出，否决股东提案时应聘请独立第三方出具《法律意见书》，但当前程序存在违规和瑕疵。 刘俊的态度更直接。他认为董事会此举“违法否决”股东提案，侵犯了持股5%以上股东的法定提案权，而且没有给予补正机会，也没有依法聘请律所出具独立法律意见书。刘俊认为，要求罢免董事是股东会审议内容，不是董事会形式审查范围，他还质疑，本次临时董事会本身未经全体董事同意，程序存在争议。 重整阶段引发多方博弈 *ST棒杰在今年披露进入预重整程序，并更新重整相关进展。此前公告显示，公司已与产业投资人美年大健康签署《重整投资协议》。根据协议，美年大健康拟作为产业投资人参与公司重整投资。市场此前普遍关注该事项是否将对公司控制权、主营业务以及后续经营方向产生影响。 回溯整个局势可以发现，随着*ST棒杰进入重整阶段，围绕董事会治理、重整投资安排及后续经营方向等...